Anti-Human CD274 (PD-L1, B7-H1) APC

Grouped product items
SizePrice Qty
25 tests
$160.00
100 tests
$335.00

Additional MIH1 Formats

Cat.No.FormatStarting From
26811-80APC$ 160.00
Catalog Number : 26811-80

description

The MIH1 monoclonal antibody specifically reacts with human CD274, also known as B7-H1 or PD-L1, a glycoprotein of the B7 family of the immunoglobulin superfamily. CD274 is expressed on the B and T lymphocytes, natural killer cells, and dendritic cells. The receptor for the B7-H1 molecule is PD-1, which contains an Immunoreceptor Tyrosine-based Inhibitory Motif (ITIM), and is expressed on activated B and T cells. The interaction between CD274 and PD-1 seems to downregulate the T and B immune responses. The MIH1 antibody is reported to be a blocking antibody.

Additional Information

Clone:
MIH1
Format:
APC
Applications:
FC
Reactivity:
Human
Isotype:
Mouse IgG1, kappa
Research Interest:Adaptive Immunity
Cell Type:B Cells, T Cells
Application:FC
Clone:MIH1
Preparation:
The product should be stored undiluted at 4°C and should be protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified utilizing affinity chromatography and unreacted dye was removed from the product.
Formulation:
Phosphate-buffered aqueous solution, ≤0.09% Sodium azide, may contain carrier protein/stabilizer, ph7.2.
References:

Marzec, M., Zhang, Q., Goradia, A., Raghunath, P. N., Liu, X., Paessler, M., ... & Wasik, M. A. (2008). Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proceedings of the National Academy of Sciences105(52), 20852-20857.

Boes, M., & Meyer-Wentrup, F. (2015). TLR3 triggering regulates PD-L1 (CD274) expression in human neuroblastoma cells. Cancer letters361(1), 49-56.

Wilcox, R. A., Feldman, A. L., Wada, D. A., Yang, Z. Z., Comfere, N. I., Dong, H., ... & Witzig, T. E. (2009). B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood114(10), 2149-2158.

© BioGems International, Inc. All rights reserved.